» Articles » PMID: 26767528

Optimal Differentiation of High- and Low-grade Glioma and Metastasis: a Meta-analysis of Perfusion, Diffusion, and Spectroscopy Metrics

Overview
Journal Neuroradiology
Specialties Neurology
Radiology
Date 2016 Jan 16
PMID 26767528
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: To perform a meta-analysis of advanced magnetic resonance imaging (MRI) metrics, including relative cerebral blood volume (rCBV), normalized apparent diffusion coefficient (nADC), and spectroscopy ratios choline/creatine (Cho/Cr) and choline/N-acetyl aspartate (Cho/NAA), for the differentiation of high- and low-grade gliomas (HGG, LGG) and metastases (MTS).

Methods: For systematic review, 83 articles (dated 2000-2013) were selected from the NCBI database. Twenty-four, twenty-two, and eight articles were included respectively for spectroscopy, rCBV, and nADC meta-analysis. In the meta-analysis, we calculated overall means for rCBV, nADC, Cho/Cr (short TE-from 20 to 35 ms, medium-from 135 to 144 ms), and Cho/NAA for the HGG, LGG, and MTS groups. We used random effects model to obtain weighted averages and select thresholds.

Results: Overall means (with 95% CI) for rCBV, nADC, Cho/Cr (short and medium echo time, TE), and Cho/NAA were: for HGG 5.47 (4.78-6.15), 1.38 (1.16-1.60), 2.40 (1.67-3.13), 3.27 (2.78-3.77), and 4.71 (3.24-6.19); for LGG 2.00 (1.71-2.28), 1.61 (1.36-1.87), 1.46 (1.20-1.72), 1.71 (1.49-1.93), and 2.36 (1.50-3.23); for MTS 5.06 (3.85-6.27), 1.35 (1.06-1.64), 1.89 (1.72-2.06), 3.14 (1.57-4.72), (Cho/NAA was not available). LGG had significantly lower rCBV, Cho/Cr, and Cho/NAA values than HGG or MTS. No significant differences were found for nADC.

Conclusions: Best differentiation between HGG and LGG is obtained from rCBV, Cho/Cr, and Cho/NAA metrics. MTS could not be reliably distinguished from HGG by the methods investigated.

Citing Articles

The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options.

von Arx C, Calderaio C, Calabrese A, Marciano B, Martinelli C, Lauro V Front Oncol. 2025; 14:1447508.

PMID: 39749036 PMC: 11693720. DOI: 10.3389/fonc.2024.1447508.


Metabolic signatures derived from whole-brain MR-spectroscopy identify early tumor progression in high-grade gliomas using machine learning.

Rivera C, Bhatia S, Morell A, Daggubati L, Merenzon M, Sheriff S J Neurooncol. 2024; 170(3):579-589.

PMID: 39180640 PMC: 11614968. DOI: 10.1007/s11060-024-04812-1.


7 Tesla magnetic resonance spectroscopic imaging predicting IDH status and glioma grading.

Cadrien C, Sharma S, Lazen P, Licandro R, Furtner J, Lipka A Cancer Imaging. 2024; 24(1):67.

PMID: 38802883 PMC: 11129458. DOI: 10.1186/s40644-024-00704-9.


Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases.

Ostojic J, Kozic D, Panjkovic M, Georgievski-Brkic B, Dragicevic D, Lovrenski A Medicina (Kaunas). 2024; 60(4).

PMID: 38674308 PMC: 11052432. DOI: 10.3390/medicina60040662.


Magnetic resonance-based imaging biopsy with signatures including topological Betti number features for prediction of primary brain metastatic sites.

Egashira M, Arimura H, Kobayashi K, Moriyama K, Kodama T, Tokuda T Phys Eng Sci Med. 2023; 46(4):1411-1426.

PMID: 37603131 DOI: 10.1007/s13246-023-01308-6.


References
1.
Spampinato M, Smith J, Kwock L, Ewend M, Grimme J, Camacho D . Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol. 2006; 188(1):204-12. DOI: 10.2214/AJR.05.1177. View

2.
Toh C, Wei K, Chang C, Ng S, Wong H . Differentiation of primary central nervous system lymphomas and glioblastomas: comparisons of diagnostic performance of dynamic susceptibility contrast-enhanced perfusion MR imaging without and with contrast-leakage correction. AJNR Am J Neuroradiol. 2013; 34(6):1145-9. PMC: 7964581. DOI: 10.3174/ajnr.A3383. View

3.
Sunwoo L, Choi S, Yoo R, Kang K, Yun T, Kim T . Paradoxical perfusion metrics of high-grade gliomas with an oligodendroglioma component: quantitative analysis of dynamic susceptibility contrast perfusion MR imaging. Neuroradiology. 2015; 57(11):1111-20. DOI: 10.1007/s00234-015-1569-6. View

4.
Lee S, Kim J, Kim Y, Lee G, Lee E, Park I . Perfusion MR imaging in gliomas: comparison with histologic tumor grade. Korean J Radiol. 2001; 2(1):1-7. PMC: 2718089. DOI: 10.3348/kjr.2001.2.1.1. View

5.
Kanno H, Nishihara H, Narita T, Yamaguchi S, Kobayashi H, Tanino M . Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas. PLoS One. 2012; 7(7):e41669. PMC: 3404002. DOI: 10.1371/journal.pone.0041669. View